US · Healthcare · Biotechnology
EPS came in at 1.28 against a street estimate of 0.97 — a beat of 32.0%.
Analysts rate Harmony Biosciences Holdings a buy (7 buy, 3 hold, 1 sell out of 11) with an average price target of $48.25.
CONFIDENT WAKIX hit record $261.3M revenue (+30% YoY), tracking $1B+ annually. BP-205 orexin-2 agonist showed encouraging Phase I PK: rapid onset, 25-hour half-life supporting once-daily dosing, no serious safety signals. Multiple data catalysts expected next 6 months. Q2 2026 Not discussed on call. Analysts pressed BP-205 scaffold novelty, potency-vs-selectivity tradeoff, competitive timeline vs Takeda, and insomnia/polyuria incidence in MAD. Management emphasized differentiation (flat structure, lower off-target risk), selectivity threshold already exceeded (140-fold safety margin), and that first-to-market is not best-in-class. Deferred granular MAD safety numbers to Q4 disclosure. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.20% |
| FMR Inc | 6.14% |
| Vanguard Portfolio Management, LLC | 4.95% |
| American Century Companies Inc | 4.36% |
| Dimensional Fund Advisors, Inc. | 4.11% |
| Vanguard Capital Management, LLC | 3.61% |
| LSV Asset Management | 3.54% |
| State Street Corp | 3.19% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Harmony Biosciences announced a planned CEO transition on October 12, 2026. • Jeffrey M. Dayno, M.D., will retire as President an | 2026-10-13 |
| Quarterly report · Q2 2026 HARMONY BIOSCIENCES HOLDINGS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product revenue Q2 2026: $261,280 thousand; Q2 2025: $200,489 thous | 2026-08-04 |
| Results announced · Q3 2026 HARMONY BIOSCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 WAKIX net revenue: $261.3 million, up 30% year-over-year vs. $200.5 million | 2026-08-04 |
| Results announced · Q3 2026 SEPARATION AGREEMENT SUMMARY – GLENN REICIN / HARMONY BIOSCIENCES HEADLINE NUMBERS • Total severance value: $562,500 ($500,000 over 12 months + $62, | 2026-07-16 |
| Shareholder vote results · Q2 2026 HARMONY BIOSCIENCES HOLDINGS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held May 14, 2026 • Total shares represented | 2026-05-14 |
| Quarterly report · Q1 2026 HARMONY BIOSCIENCES HOLDINGS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product revenue Q1 2026: $215,387 thousand vs. $184,733 thousand Q1 | 2026-05-07 |
| Results announced · Q2 2026 HARMONY BIOSCIENCES Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 net product revenue: $215.4 million, up 17% year-over-year from $184.7 mill | 2026-05-07 |
| Proxy statement · Q2 2026 HARMONY BIOSCIENCES HOLDINGS, INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Four Class III Directors — Vote FO | 2026-04-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2026 net product revenue guidance provided; 2025 preliminary results announced Harmony Biosciences issued a preliminary earnings announcement for Q4 and full-year 2025 results on January 12, 2026. The company provided 2026 net product revenue guidance and updated inves | 2026-01-12 |
| Preliminary Q3 2025 net product revenue announced with updated 2025 guidance Harmony Biosciences Holdings announced preliminary Q3 2025 net product revenue results and updated 2025 full-year guidance on October 23, 2025. However, this 8-K filing itself contains only | 2025-10-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Harmony Biosciences Holdings — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.